Mast cells and cutaneous malignancies
- PMID: 16258517
- DOI: 10.1038/modpathol.3800474
Mast cells and cutaneous malignancies
Abstract
This paper reviews the role of mast cells in the development and progression of basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Mast cells accumulate around cutaneous malignancies. Current evidence suggests that mast cells contribute to the tumorigenesis of cutaneous malignancies through four mechanisms. (1) Immunosuppression: Ultraviolet-B radiation, the most important initiator of cutaneous malignancies, activates mast cells. Upon irradiation of the skin, trans-urocanic acid in the epidermis isomerizes to cis-urocanic acid, which stimulates neuropeptide release from neural c-fibers. These neuropeptides in turn trigger histamine secretion from mast cells, leading to suppression of the cellular immune system. (2) Angiogenesis: Mast cells are the major source of vascular endothelial growth factor in basal cell carcinoma and malignant melanoma. Vascular endothelial growth factor is one of the most potent angiogenic factors, which also induces leakage of other angiogenic factors across the endothelial cell wall into the matrix. Mast cell proteases reorganize the stroma to facilitate endothelial cell migration. As well, heparin, the dominant mast cell proteoglycan, assists in blood-borne metastasis. (3) Degradation of extracellular matrix: Through its own proteases, and indirectly via interaction with other cells, mast cells participate in degradation of the matrix, which is required for tumor spread. (4) Mitogenesis: Mast cell mediators including fibroblast growth factor-2 and interleukin-8 are mitogenic to melanoma cells. Current evidence supports an accessory role for mast cells in the development and progression of cutaneous malignancies. Emerging data, however, also suggest that mast cells might, in fact, have opposing roles in tumor biology, and the microenvironment could polarize mast cells to possess either promoting or inhibitory effects on tumors.
Similar articles
-
Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: implications for melanoma progression.J Cutan Pathol. 1996 Dec;23(6):495-505. doi: 10.1111/j.1600-0560.1996.tb01441.x. J Cutan Pathol. 1996. PMID: 9001979
-
Controversial role of mast cells in skin cancers.Exp Dermatol. 2017 Jan;26(1):11-17. doi: 10.1111/exd.13107. Epub 2016 Oct 24. Exp Dermatol. 2017. PMID: 27305467
-
Mast cells in cutaneous tumors: innocent bystander or maestro conductor?Int J Dermatol. 2014 Jul;53(7):806-11. doi: 10.1111/j.1365-4632.2012.05745.x. Epub 2013 Apr 28. Int J Dermatol. 2014. PMID: 23621615
-
Dermatological aspects of angiogenesis.Br J Dermatol. 2002 Nov;147(5):841-52. doi: 10.1046/j.1365-2133.2002.05073.x. Br J Dermatol. 2002. PMID: 12410692 Review.
-
Dermal mast cells affect the development of sunlight-induced skin tumours.Exp Dermatol. 2012 Apr;21(4):241-8. doi: 10.1111/j.1600-0625.2012.01438.x. Epub 2012 Jan 26. Exp Dermatol. 2012. PMID: 22276860 Review.
Cited by
-
Cell Component and Function of Tumor Microenvironment in Thyroid Cancer.Int J Mol Sci. 2022 Oct 20;23(20):12578. doi: 10.3390/ijms232012578. Int J Mol Sci. 2022. PMID: 36293435 Free PMC article. Review.
-
Immunotherapy in Basal Cell Carcinoma.J Clin Med. 2024 Sep 26;13(19):5730. doi: 10.3390/jcm13195730. J Clin Med. 2024. PMID: 39407789 Free PMC article. Review.
-
Contribution of Fibroblast and Mast Cell (Afferent) and Tumor (Efferent) IL-6 Effects within the Tumor Microenvironment.Cancer Microenviron. 2012 Apr;5(1):83-93. doi: 10.1007/s12307-012-0098-7. Epub 2012 Feb 8. Cancer Microenviron. 2012. PMID: 22314376 Free PMC article.
-
Increase in CD30 ligand/CD153 and TNF-alpha expressing mast cells in basal cell carcinoma.Cancer Immunol Immunother. 2007 Sep;56(9):1407-15. doi: 10.1007/s00262-007-0290-7. Epub 2007 Feb 1. Cancer Immunol Immunother. 2007. PMID: 17268792 Free PMC article.
-
Mast cells and T-lymphocytes in juvenile angiofibromas.Eur Arch Otorhinolaryngol. 2007 Jul;264(7):769-75. doi: 10.1007/s00405-007-0262-8. Epub 2007 Feb 20. Eur Arch Otorhinolaryngol. 2007. PMID: 17310347
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials